Evidence map›Paper›PMID 39503942›Full record

ArticleQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2025

Identification of meaningful individual-level change thresholds for worsening on the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE®).

Minji K Lee, Sandra A Mitchell, Ethan Basch, Gina L Mazza, Blake T Langlais, Gita Thanarajasingam, Brenda F Ginos, Lauren Rogak, Eric A Meek, Jennifer Jansen and 9 more

2 registry-linked trialsAbstract read
In one paragraph

Article in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02158637 completednot on this map

Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

TypeobservationalSponsorMayo ClinicRan2010 to 2017Enrolled1,100ConditionsCancer
NCT03249090 nacompletednot on this map

"PRO-TECT" Patient Reported Outcomes to Enhance Cancer Treatment

TypeinterventionalSponsorAlliance Foundation Trials, LLC.Ran2017 to 2023Enrolled1,197ConditionsMetastatic CancerArmsPatient Self-Reporting of Symptoms, Usual Care Delivery
3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Symptoms experienced during the first 4 months of chemotherapy administration: a longitudinal cohort study in an Australian cancer treatment unit.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Minji K LeeAlliance Foundation Trials Statistics and Data Center, Mayo Clinic, 200 1st Ave SW, Rochester, MN, 55902, USA. Lee.Minji@mayo.edu.ORCID http://orcid.org/0000-0002-1301-4319
Sandra A MitchellNational Cancer Institute, Bethesda, MD, USA.
Ethan BaschLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Gina L MazzaAlliance Foundation Trials Statistics and Data Center, Mayo Clinic, Scottsdale, AZ, USA.
Blake T LanglaisDepartment of Quantitative Health Sciences, Mayo Clinic, Scottsdale, AZ, USA.
Gita ThanarajasingamDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Brenda F GinosAlliance Foundation Trials Statistics and Data Center, Mayo Clinic, Scottsdale, AZ, USA.
Lauren RogakDepartment of Quantitative Health Sciences, Mayo Clinic, Scottsdale, AZ, USA.
Eric A MeekDepartment of Quantitative Health Sciences, Mayo Clinic, Scottsdale, AZ, USA.
Jennifer JansenLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Allison M DealLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Philip CarrLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Victoria S BlinderMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Mattias JonssonLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Gita N ModyLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Tito R MendozaNational Cancer Institute, Bethesda, MD, USA.
Antonia V BennettLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Deborah SchragMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Amylou C DueckAlliance Foundation Trials Statistics and Data Center, Mayo Clinic, Scottsdale, AZ, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI David Darr · 1985 to 2026
$201.5M
Analyzing and Interpreting PRO-CTCAE with CTCAE and Other Clinical Data to Characterize Drug TolerabilityU01CA233046 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BASCH, ETHAN M., DUECK, AMYLOU CONSTANCE · 2018 to 2023
$3.0M
Improving Thoracic Surgical Care using electronic Patient-Reported Outcomes (ePROs)K23HL157765 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Gita Natwar Mody · 2022 to 2026
$1.0M
NCI NIH HHS 5-P30-CA016086NCI NIH HHS HHSN261200800043CNCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016086NCI NIH HHS U01 CA233046NHLBI NIH HHS K23 HL157765
6 · The paper itself

Abstract

backgroundWe derived meaningful individual-level change thresholds for worsening in selected patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE®) items and their composite scores.

methodsWe used two data sources, the PRO-TECT trial (Alliance AFT-39) that collected PRO-CTCAE data from adults with advanced cancer at 26 United States (U.S.) community oncology practices and the PRO-CTCAE validation study that collected PRO-CTCAE data from adults undergoing chemotherapy or radiation therapy at nine U.S. cancer centers or community oncology practices. Both studies administered selected PRO-CTCAE items and EORTC QLQ-C30 scales. Conceptually, relevant QLQ-C30 domains were used as anchors to estimate meaningful change thresholds for deterioration in corresponding PRO-CTCAE items and their composite scores. Items or composites with ǀρǀ ≥ 0.30 correlation with QLQ-C30 scales were included. Changes in PRO-CTCAE scores and composites were estimated for patients who met or exceeded a 10-point deterioration on the corresponding QLQ-C30 scale. Change scores were computed between baseline and the 3-month timepoint in PRO-TECT, and in the PRO-CTCAE validation study between baseline and a single follow-up visit that occurred between 1 and 7 weeks later. For each PRO-CTCAE item, change scores could range from - 4 to 4; for a composite, change scores could range from - 3 to 3.

resultsChange scores in QLQ-C30 and PRO-CTCAE were available in 406 and 792 patients in PRO-TECT and the validation study, respectively. Across QLQ-C30 scales, the proportion of patients with a 10-point or greater worsening on QLQ-C30 ranged from 15 to 30% in the PRO-TECT data and 13% to 34% in the validation data. Across PRO-CTCAE items, anchor-based meaningful change estimates for deterioration ranged from 0.05 to 0.30 (mean 0.19) in the PRO-TECT data and from 0.19 to 0.53 (mean 0.36) in the validation data. For composites, they ranged from 0.06 to 0.27 (mean 0.17) in the PRO-TECT data and 0.22 to 0.51 (mean 0.37) in the validation data.

conclusionIn both datasets, the minimal meaningful individual-level change threshold for worsening was one point for all items and composite scores. CLINICALTRIALS: gov: NCT03249090 (AFT-39), NCT02158637 (MC1091).

Indexed as

Antineoplastic AgentsDrug-Related Side Effects and Adverse ReactionsNeoplasmsPatient Reported Outcome MeasuresQuality of LifeAdultAgedFemaleHumansMaleMiddle AgedMulticenter Studies as TopicObservational Studies as TopicPsychometricsRandomized Controlled Trials as TopicSurveys and QuestionnairesAntineoplastic AgentsIndividual-level meaningful change thresholdMeaningful worseningPRO-CTCAE

Identifiers

PMID39503942
PMCPMC11865169

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.